| Oscar Insurance Guidelines | sodium oxybate Xyrem | 2025-07-01 |
| Aetna | Trastuzumab (Herceptin and biosimilars), Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) | 2025-07-01 |
| Aetna | Lysosomal Storage Disorder Treatments | 2025-07-01 |
| Aetna | Romosozumab-aqqg (Evenity) | 2025-07-01 |
| Aetna | Mirikizumab-mrkz (Omvoh) | 2025-07-01 |
| UHC Medicare Advantage | Neurologic Services and Procedures – Medicare Advantage Medical Policy | 2025-07-01 |
| UHC Medicare Advantage | Spinal Cord Stimulators for Chronic Pain – Medicare Advantage Medical Policy | 2025-07-01 |
| UHC Medicare Advantage | Varicose Veins Treatment and Other Vein Embolization Procedures – Medicare Advantage Medical Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Adzynma (ADAMTS13, Recombinant-Krhn) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Amondys 45® (Casimersen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |